subClinical Environmental Health  News (sCEHN ©)

25 Feb - March 1 2014, Madrid Spain With over 300 medical doctors, research scientists and medical specialists in attendance for the 5 day conference included the latest studies associated with exposure and the effects of clinically important fungi. With over 100 presentations from clinic to lab to bedside. The emphasis for health risk investigators for the identification of and fungal resistance of these fungi. Aspergillosis 6th was launched with 2 days of pre-conference workshop and classes .with entitled areas of study and presentation of high interest included Aspergillus biology, factors affecting Aspergillus pathogenesis. antifungal resistance and chronic and allergic Aspergillosis. United States delegate Prof J Dumanov, clinical research medical mycologist (Mycological Institute EU US 1997) interviewed for subClinical Environmental Health  News (sCEHN ©) digesting the most recent findings of interest relating to human health and exposure risk assessments.

josef dumanov presentation subClinical Protocols

Diagnostic algorithm and case reports of subClinical Investigation™ presented

at Aspergillosis 6th Madrid Spain February 2014


Professor these last five days have been very busy with nearly 200 presentations how can we best summarize the take home message?

Prof: The answer is that for each of the attendees it is a matter of their professional areas of practice or research. From the diagnostic lab to bedside it appears there was the most interest for the emerging identification of newly identified cryptic Aspergillus species and their pharmacology and specifically to antifungal resistance by this genus of mold fungi.

What makes the Aspergillus noteworthy given there are so many species?

Prof: You first have to understand the clinical relevancy of exposure to the genus Aspergillus. It must be known that over eighty percent of fungal mold infection and diseases are associated with this genus. Within this genus there are are over 250 species with a few that truly stand out as being pathogenic is fumigatus. Then we have cryptic species of this genus that present new challenges for diagnosis.

Just what are cryptic species and why is it important to understand them?

Prof: Cryptic species are genetic sub-types that have developed in ways that make them resistant to antifungals. This presents a new and difficult challenge to medical doctors in making a determination for drug treatment. Fortunately new tests have been developed and others are still under development.

Given your clinical exposure research work relating to exposure to mold what is most important for the possibly exposed to know?

Prof: This is the area of research that in which consists of my work developing the subClinical Protocols™ over 15 years of related activity both in academia and medical specialty. Having been involved in countless health exposures cases where mold fungi was suspected to be involved in diseases or disorders. In fact my findings often proved to be other causative agents from toxins, allergens, bacteria or other fungi there continues to be an unmet need for properly trained investigators. Many of my clients and patients have been medical doctors and health care professionals. Medical professionals fully understand the level of integration required and the applied differentials for this practice as demonstrated in my presentation at this conference.

How would you best describe the diagnostic techniques and methods of the subClinical Protocols?

Prof: Medical expertise and medical science demands a full understanding of molecular biology for diagnosis and then exposure risk factors to determine the cause of an individuals disease. We were honored that the complexity of exposure assessment and the methods of subCLinical investigation as developed was recognized as being the most "comprehensive" at this conference.


*No assn with or by the ABIH or their CIH certification schema